This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2025-04-13), Zeo ScientifiX's share price is $1.90. Zeo ScientifiX's Median PS Value is $0.00. Therefore, Zeo ScientifiX's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Zeo ScientifiX's Median PS Value or its related term are showing as below:
ZEOX's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.67 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Zeo ScientifiX Median PS Value Historical Data
The historical data trend for Zeo ScientifiX's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zeo ScientifiX's Median PS Value
For the Biotechnology subindustry, Zeo ScientifiX's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Zeo ScientifiX's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.718.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (OTCPK:ZEOX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Zeo ScientifiX's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.90
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX Median PS Value Related Terms
Thank you for viewing the detailed overview of Zeo ScientifiX's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZEOX has been successfully added to your 